|
Disease Stage |
|
| Lobular Carcinoma in Situ (LCIS) |
NONE |
| Ductal Carcinoma in Situ (DCIS) |
NONE |
| Completion of 5 years of Hormonal Therapy |
NSABP B-42: Five years of Letrozole versus Placebo (Can enroll while taking the Letrozole in years 3-5 and will the Letrozole will be provided)
|
| ER & / or PR Positive Nodes Negative | PACCT-1 ONCOTYPE DX Assay Recurrance Score <11 Hormonal therapy, Recurrence Score 11-25 Hormonal Therapy versus Chemotherapy / Hormonal therapy, Recurrence Score > 25 Hormonal Therapy / Chemotherapy |
| Stage I / II/ III | CTSU S0307: Zolendronic Acid versus Clodronate versus Ibandronate |
Stage 0, I, or II ER/PR Negative--receiving 3 - 8 months of an alkylating agent
|
Pre-Menopausal Only--ECOG S0230 Hormonal treatment during chemotherapy to reduce ovarian failure following chemotherapy |
| Stage 0,I or II (tumor must be 3cm or smaller)—Must have had prior lumpectomy, up to 3 axillary nodes can be histologically positive |
NSABP B-39: Whole Breast Irradiation (25 treatments in 5 weeks) versus Partial Breast Irradiation (10 treatments in 5 days) |
Any T, Any N, M0 ER and/or PR positive, must be 6 months from chemotherapy completion (if given)--PRE-MENOPAUSAL WOMEN ONLY |
CTSU IBSCG 24-02: Tamoxifen for 5 years versus Ovarian Function Suppression (either using drugs / Radiation Therapy / surgery) plus Tamoxifen for 5 years versus Ovarian Function Suppression plus Exemestane for 5 years |
T1a - 3, N0 - 3
ER / PR Negative
HER2 Negative |
Bo20289 BEATRICE: Chemotherapy (Physician Choice) plus Bevacizumab |
T1-3, N0-3 and HER2 Positive
If Node Negative, must have one of the following:
Tumor size > 2cm
ER / PR negative
Histologic &/or nuclear grade 2 or 3
Age < 35 years |
NSABP B-44 (BETH): Docetaxel + Carboplatin + Trastuzumab (every 3 weeks for 6 cycles. This is given with or without Bevacizumab. Followed by continued Trastuzumab for a complete year of treatment (if Bevacizumab) was given initial, that will continue also for the entire year. |
HER 2 positive
Node positive
If Node Negative, tumor size must be > / = 1cm
Prior treatment with at least 4 cycles of an Anthracycline
|
CTSU N063D (ALTTO) : After the inital chemotherapy the following will occur:
Tratuzumab every 3 weeks for 52 weeks versus Lapatinib orally for 52 weeks versus Tratuzumab every 3 weeks for 12 weeks, then 6 weeks off and then Lapatinib orally for 34 weeks versus Tratuzumab every 3 weeks and Lapatinib orally for 52 weeks.
If Paclitaxel is given, it will be weekly for the first 12 weeks. During this time, the Tratuzumab will also be given weekly. |
HER 2 negative & must have one of the following:
At least one node positive
ER negative & tumor size > / = 1cm
ER Positive & tumor size > / = 5cm
ER positive & tumor size < / = 1cm, but < 5cm with a recurrence score of > / = 11 |
ECOG E5103 Adriamycin + Cytoxan (either every 2 weeks or every 3 weeks) plus Bevacizumab / placebo (4 cycles) followed by Paclitaxel plus Bevacizumab / placebo (4 Cycles). One group will continue the Bevacizumab every 3 weeks for a total of 10 more cycles. |
Core biopsy only & Greater than or equal to 2.0cm tumor size & HER2 Negative
Core biopsy only & Greater than or equal to 2.0cm tumor size & HER2 Positive
HER2+, locally advanced-NeoAdjuvant OR Stage III after surgery |
NSABP B-40: Docetaxel + Adriamycin / Cytoxan (AC) with or without Bevacizumab Versus Docetaxel + Capecitabine + AC with or without Bevacizumab Versus Docetaxel + Gemzar + AC with or without Bevacizumab, then surgery and continued Bevacizumab if received before.
NSABP B-41: Adriamycin + Cytoxan (AC) followed by Trastuzumab + Lapatinib versus + Lapatinib + weekly Paclitaxel
NSABP FB-05 Epirubicin + Cyclophosphamide, then Docetaxel + Herceptin + Bevacizumab |
| Stage II / III, ER+, Postmenopausal--NeoAdjuvant |
CTSU Z1031: 16 weeeks versus 18 weeks of Exemestane, Letrozole or Anastroxole |
| First local and/or regional recurrence |
NSABP B-37: Observation with or without Radiation, Hormonal therapy, and/or Herceptin versus Chemotherapy (selected by the physician) with or without Radiation, Hormonal therapy, and/or Herceptin |
Breast Cancer Clinic
